Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: enzymatic studies.

por Wang, J., Biedermann, K. A., Wolf, C. R., Brown, J. M.
Publicado 1993

The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines

por Kostrzewa-Nowak, D, Paine, M J I, Wolf, C R, Tarasiuk, J
Publicado 2005

Defining the Contribution of CYP1A1 and CYP1A2 to Drug Metabolism Using Humanized CYP1A1/1A2 and Cyp1a1/Cyp1a2 Knockout Mice

por Kapelyukh, Y., Henderson, C. J., Scheer, N., Rode, A., Wolf, C. R.
Publicado 2019

Menadione-resistant Chinese hamster ovary cells have an increased capacity for glutathione synthesis.

por Vallis, K. A., Reglinski, J., Garner, M., Bridgeman, M. M., Wolf, C. R.
Publicado 1997

Regulation of cytochrome P450 gene expression in human colon and breast tumour xenografts.

por Smith, G., Harrison, D. J., East, N., Rae, F., Wolf, H., Wolf, C. R.
Publicado 1993

Cross-talk between signalling pathways and the multidrug resistant protein MDR-1

por Ding, S, Chamberlain, M, McLaren, A, Goh, L-b, Duncan, I, Wolf, C R
Publicado 2001

Molecular genetic analysis of the cytochrome P450-debrisoquine hydroxylase locus and association with cancer susceptibility.

por Smith, C A, Moss, J E, Gough, A C, Spurr, N K, Wolf, C R
Publicado 1992

Glutathione-s-transferase pi expression in leukaemia: a comparative analysis with mdr-1 data.

por Holmes, J., Wareing, C., Jacobs, A., Hayes, J. D., Padua, R. A., Wolf, C. R.
Publicado 1990

Activating K-Ras mutations outwith ‘hotspot’ codons in sporadic colorectal tumours – implications for personalised cancer medicine

por Smith, G, Bounds, R, Wolf, H, Steele, R J C, Carey, F A, Wolf, C R
Publicado 2010

Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer

por Smith, G, Ng, M T H, Shepherd, L, Herrington, C S, Gourley, C, Ferguson, M J, Wolf, C R
Publicado 2012

Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines

por Sawers, L, Ferguson, M J, Ihrig, B R, Young, H C, Chakravarty, P, Wolf, C R, Smith, G
Publicado 2014

MicroRNA-224 is associated with colorectal cancer progression and response to 5-fluorouracil-based chemotherapy by KRAS-dependent and -independent mechanisms

por Amankwatia, E B, Chakravarty, P, Carey, F A, Weidlich, S, Steele, R J C, Munro, A J, Wolf, C R, Smith, G
Publicado 2015

Glutathione S-transferase isoenzymes in human tumours and tumour derived cell lines.

por Lewis, A. D., Forrester, L. M., Hayes, J. D., Wareing, C. J., Carmichael, J., Harris, A. L., Mooghen, M., Wolf, C. R.
Publicado 1989

Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours

por Weidlich, S, Walsh, K, Crowther, D, Burczynski, M E, Feuerstein, G, Carey, F A, Steele, R J C, Wolf, C R, Miele, G, Smith, G
Publicado 2011

An Extensively Humanized Mouse Model to Predict Pathways of Drug Disposition and Drug/Drug Interactions, and to Facilitate Design of Clinical Trials

por Henderson, C.J., Kapelyukh, Y., Scheer, N., Rode, A., McLaren, AW., MacLeod, A.K., Lin, D., Wright, J., Stanley, L.A., Wolf, C.R.
Publicado 2019